Find a Commonwealth Resource
Patent AT-E400297-T1: [Translated] CTGF AS A TARGET MOLECULE IN THE TREATMENT OF MICROALBUMINURIA IN PATIENTS WITH DIABETIC NEPHROPATHY
HealthData.Gov
Updated Oct 29, 2026
About this dataset
The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.
Data and resources (1)
- HTML
Official Data Source
Access the complete Patent AT-E400297-T1: [Translated] CTGF AS A TARGET MOLECULE IN THE TREATMENT OF MICROALBUMINURIA IN PATIENTS WITH DIABETIC NEPHROPATHY on the official website.
Modified Apr 29, 2026